The first transcatheter device designed to deliver

The Right Solution for the Right Side

Edwards Cardioband Tricuspid Valve Reconstruction System
Tricuspid regurgitation is largely undertreated.

Patient mortality is significant.

- Many patients diagnosed with tricuspid regurgitation are medically managed.
- Patients may experience debilitating symptoms, with few treatment options.

<1% are treated surgically¹

>36% one-year mortality rate for patients with severe tricuspid regurgitation²

* Based on US data.
The first-ever, CE Marked transcatheter tricuspid annular reduction system

Cardioband Tricuspid Valve Reconstruction System.

Designed to safely and effectively reduce tricuspid regurgitation through annular reduction.\(^3\)

- **Restores** valve to a more functional state, facilitating leaflet coaptation
- **Enables** annular reduction based on each patient’s anatomy
- **Supports** real-time adjustment and confirmation of procedural results
Facilitates leaflet coaptation. Preserves native anatomy.

Cardioband Tricuspid System addresses the main physiological cause of tricuspid regurgitation: annular dilatation.

- Supra-annular fixation preserves native anatomy—keeping future treatment options open

Real-time intraprocedural adjustment and confirmation of results

ECHO AT BASELINE
Transesophageal echocardiogram (TEE) shows tricuspid regurgitation at baseline

ECHO POST-PROCEDURE
Real-time, intra-procedural confirmation of reduction in tricuspid regurgitation

Images courtesy of Bonn University Hospital
A reproducible and standardised procedure.

Precise positioning in patient anatomy

1. Access
Insert Cardioband delivery system into the right atrium using a transfemoral approach.

2. Deploy
Deploy implant via a steerable catheter to navigate around the tricuspid annulus, securing the implant with stainless steel anchors.

3. Adjust and Reduce TR
Introduce the size adjustment tool over a wire and rotate the adjustment knob clockwise for implant contraction.
Clinical results show the Cardioband Tricuspid System safely and effectively reduces tricuspid regurgitation and improves quality of life.³
Driven by a passion to help patients.

With the first-ever introduction of an advanced, CE Marked transcatheter solution for the treatment of tricuspid regurgitation, Edwards Lifesciences continues to innovate in meaningful and lasting ways for both physicians and patients.

For more information, please visit www.edwards.com/CardiobandTR

References